RecruitingNCT05007379
Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids
Cohort Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids (CARMA)
Sponsor
Centre Oscar Lambret
Enrollment
100 participants
Start Date
Nov 2, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
Cell-based immune therapy using modified macrophages is a promising therapeutic approach in breast cancer. The objective of this cohort study is to collect tumor samples to develop patients' derived organoids to test the antitumor activity of newly developed CAR-macrophages. Other biological samples will be collected such as blood to analyze the host inflammatory status.
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria6
- Male or female aged 18 years or more
- Histologically confirmed breast cancer at any stage
- Requiring surgery or tumor biopsy as standard of care
- Any or no systemic treatment
- Signed informaed consent
- Health insurance coverage
Exclusion Criteria1
- Opposed to biospecimen collection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05007379
Related Trials
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer
NCT073490692 locations
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
NCT074245475 locations
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT0722226712 locations
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations